BTCS Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BTCS Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.07M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.34M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.69M | Mar 21, 2024 |
| FY2018 | Dec 31, 2017 | $4.5K | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $355.2K | Oct 12, 2018 |
| FY2016 | Dec 31, 2015 | $506.2K | Jun 23, 2017 |
| FY2015 | Dec 31, 2014 | $38.2K | Feb 19, 2016 |
| FY2014 | Dec 31, 2013 | $29.3K | Apr 15, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.07M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.34M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.69M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.21M | Mar 31, 2023 |
| FY2018 | Dec 31, 2017 | $4.5K | Feb 6, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.01M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $946.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $979.9K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.27M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $944.9K | Mar 31, 2023 |
| FY2018 | Dec 31, 2017 | $4.3K | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $91.3K | Oct 12, 2018 |
| FY2016 | Dec 31, 2015 | $216.1K | Jun 23, 2017 |
| FY2015 | Dec 31, 2014 | $31.5K | Feb 19, 2016 |
| FY2014 | Dec 31, 2013 | $29.3K | Apr 15, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.35M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.27M) | Mar 26, 2026 |
| FY2023 | Dec 31, 2023 | $7.82M | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | ($15.89M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($16.05M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.56M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.64M) | Jan 26, 2021 |
| FY2019 | Dec 31, 2018 | ($826.4K) | Jun 22, 2020 |
| FY2018 | Dec 31, 2017 | ($45.46M) | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | ($44.27M) | Oct 12, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | ($990.2K) | Feb 6, 2019 |
| FY2018 | Dec 31, 2017 | ($1.57M) | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | ($1.46M) | Oct 12, 2018 |
| FY2016 | Dec 31, 2015 | ($8.20M) | Jun 23, 2017 |
| FY2015 | Dec 31, 2014 | ($14.56M) | Feb 19, 2016 |
| FY2014 | Dec 31, 2013 | $17.1K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | ($29.4K) | Mar 28, 2014 |
| FY2012 | Dec 31, 2011 | ($680.8K) | Jan 29, 2014 |
| FY2011 | Dec 31, 2010 | $92.5K | Jan 28, 2014 |
| FY2012 | Dec 31, 2009 | ($262.5K) | Mar 28, 2013 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $679.4K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $755.8K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $687.3K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $611.8K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $712.7K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $45.5K | Mar 11, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.78M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($3.53M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($3.56M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($776.8K) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($4.86M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.97M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.50M) | Jan 26, 2021 |
| FY2019 | Dec 31, 2018 | ($505.6K) | Jun 22, 2020 |
| FY2018 | Dec 31, 2017 | ($1.49M) | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | ($828.5K) | Oct 12, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.8K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.6K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.3K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $5.4K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $10.5K | Mar 31, 2023 |
| FY2019 | Dec 31, 2018 | $2.6K | Jun 22, 2020 |
| FY2018 | Dec 31, 2017 | $1.5K | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $14.6K | Oct 12, 2018 |
| FY2016 | Dec 31, 2015 | $553.1K | Jun 23, 2017 |
| FY2015 | Dec 31, 2014 | $345.4K | Feb 19, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.63M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $38.25M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $27.15M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $9.92M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $14.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.55M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $421.4K | Jan 26, 2021 |
| FY2019 | Dec 31, 2018 | $63.2K | Jun 22, 2020 |
| FY2018 | Dec 31, 2017 | $589.4K | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | $98.1K | Oct 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.22M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.25M | Mar 26, 2026 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $139.42M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $34.00M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $26.17M | Mar 26, 2026 |
| FY2023 | Jan 1, 2023 | $14.32M | Mar 21, 2024 |
| FY2024 | Dec 31, 2022 | $14.32M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $12.10M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.04M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($183.8K) | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | ($256.0K) | Jan 26, 2021 |
| FY2019 | Dec 31, 2017 | $513.4K | Jun 22, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($173.30M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($139.95M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($138.68M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($151.48M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($135.59M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($119.54M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($116.98M) | Jan 26, 2021 |
| FY2019 | Dec 31, 2018 | ($115.34M) | Jun 22, 2020 |
| FY2018 | Dec 31, 2017 | ($114.52M) | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | ($69.05M) | Oct 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.98M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.46M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.15M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.40M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $524.1K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $143.1K | Jan 26, 2021 |
| FY2019 | Dec 31, 2018 | $52.1K | Jun 22, 2020 |
| FY2018 | Dec 31, 2017 | $303.3K | Feb 6, 2019 |
| FY2018 | Dec 31, 2016 | $95.1K | Feb 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.85M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 18.72M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 15.32M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 13.11M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 10.53M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 4.20M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 19.83M | Jan 26, 2021 |
| FY2019 | Dec 31, 2018 | 12.52M | Jun 22, 2020 |
| FY2018 | Dec 31, 2017 | 363.04M | Feb 6, 2019 |
| FY2017 | Dec 31, 2016 | 16.10M | Oct 12, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $630.8K | Mar 21, 2024 |